Kaplan–Meier survival analysis revealed that the patients with higher HHLA2 and IR-neoAg load had the worst outcome (Fig. 4C), which provides further support that HHLA2 may be a druggable target for treating MM in the future [32]. Here, HHLA2 is linked to Miyoshi myopathy.